DOI: 10.36347/sjmcr.2023.v11i03.035

Pages: 385-388

Coronavirus disease 2019 (COVID-19) is a public health emergency of international concern. The global population lacks immunity to COVID-19 and is generally susceptible. It is reported that at least 2% of patients with COVID-19 have underlying lung disease, which is related to severe clinical manifestations and higher mortality compared with those without chronic lung diseases [1]. The existence of underlying conditions, especially chronic respiratory diseases, with long-term drug treatment, may affect the progress, treatment and prognosis of COVID-19. Here, we report the case of a 50 year old female who is a known case of Kartagener’s syndrome and developed infective exacerbation of bronchiectasis complicating severe COVID-19 pneumonia with hypercapneoic respiratory failure which responded to anti-pseudomonal antibiotic coverage and non-invasive positive pressure ventilation therapy. The case in the current study indicated that SARS-CoV-2 infection precipitated bronchiectasis exacerbation in a patient of primary ciliary dyskinesia as limited data is available regarding this association and there is concern about its poor outcome.